Teresa De Haro Garcia,Michael Deligny,Jag Paul Heer,Joanna Rachel Quincey,Mengyang Xuan,Zhaoning Zhu,Daniel Christopher Brookings,Mark Daniel Calmiano,Yves Evrard,Martin Clive Hutchings,James Andrew J
申请号：
US16220847
公开号：
US20190367535A1
申请日:
2018.12.14
申请国别(地区):
US
年份:
2019
代理人:
摘要：
A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders； neurological and neurodegenerative disorders； pain and nociceptive disorders； cardiovascular disorders； metabolic disorders； ocular disorders； and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
